Subtopic Deep Dive
Clonal Hematopoiesis in AML Precursor States
Research Guide
What is Clonal Hematopoiesis in AML Precursor States?
Clonal hematopoiesis (CH) in AML precursor states refers to age-related expansion of somatic mutations in hematopoietic stem cells, particularly DNMT3A, TET2, and ASXL1, that can progress to acute myeloid leukemia (AML) or myelodysplastic syndromes.
CH of indeterminate potential (CHIP) is distinguished from myelodysplastic syndromes by the absence of cytopenias and dysplasia (Steensma et al., 2015, 1859 citations). Common mutations include TET2 in 15% of myeloid cancers (Delhommeau et al., 2009, 1720 citations). WHO classifications integrate CH into myeloid neoplasm diagnostics (Arber et al., 2016, 9991 citations; Khoury et al., 2022, 3500 citations).
Why It Matters
CH identifies individuals at elevated risk for AML progression, enabling surveillance in at-risk populations (Steensma et al., 2015). ELN guidelines incorporate CH mutations into AML risk stratification and management (Döhner et al., 2017, 5711 citations). CH links to therapy-related AML and influences prognostic scores in precursor states (Jaiswal et al., 2017, 2448 citations).
Key Research Challenges
Distinguishing CHIP from MDS
CHIP lacks cytopenias unlike MDS, complicating diagnosis without dysplasia assessment (Steensma et al., 2015, 1859 citations). Variant allele frequency thresholds and mutation patterns require precise genomic profiling. WHO criteria updates address overlap but need validation (Arber et al., 2016).
Predicting AML Progression Risk
CHIP mutations like DNMT3A/TET2 confer variable AML risk needing longitudinal studies (Jaiswal et al., 2017). Prognostic models integrate CH with ELN scores but lack specificity (Döhner et al., 2017). Serial monitoring identifies high-risk clones yet optimal thresholds remain unclear.
Mutation-Specific Mechanisms
TET2 mutations drive myeloid neoplasm progression but functional impacts vary (Delhommeau et al., 2009). Epigenetic effects of DNMT3A/ASXL1 in precursor states require mechanistic studies. Integration with gene-expression profiling aids subclassification (Bullinger et al., 2004).
Essential Papers
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian et al. · 2016 · Blood · 10.0K citations
Abstract The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identi...
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner, Elihu H. Estey, David Grimwade et al. · 2016 · Blood · 5.7K citations
Abstract The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by...
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury, Éric Solary, Oussama Abla et al. · 2022 · Leukemia · 3.5K citations
A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders
Róbert Královics, Francesco Passamonti, Andreas Buser et al. · 2005 · New England Journal of Medicine · 3.4K citations
A high proportion of patients with myeloproliferative disorders carry a dominant gain-of-function mutation of JAK2.
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
Siddhartha Jaiswal, Pradeep Natarajan, Alexander J. Silver et al. · 2017 · New England Journal of Medicine · 2.4K citations
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP), which is defined as the presence of an expanded somatic blood-cell clone in persons without other hematologic abnormalities, is c...
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]
HJ Kolb, A Schattenberg, JM Goldman et al. · 1995 · Blood · 2.0K citations
The immune reactivity of allogeneic lymphocytes plays a major role in the control of leukemia after bone marrow transplantation. In patients with recurrent leukemia after marrow transplantation, ch...
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma, Rafael Bejar, Siddhartha Jaiswal et al. · 2015 · Blood · 1.9K citations
Abstract Recent genetic analyses of large populations have revealed that somatic mutations in hematopoietic cells leading to clonal expansion are commonly acquired during human aging. Clonally rest...
Reading Guide
Foundational Papers
Start with Steensma et al. (2015) for CHIP definition and MDS distinction; Arber et al. (2016) for WHO integration into myeloid classifications; Delhommeau et al. (2009) for TET2 mutation prevalence in precursors.
Recent Advances
Khoury et al. (2022) updates 5th WHO edition on CH in neoplasms; Döhner et al. (2017) ELN guidelines for AML risk with CH; Jaiswal et al. (2017) on progression risks.
Core Methods
Sequencing for DNMT3A/TET2/ASXL1 detection; gene-expression profiling for subclasses (Bullinger et al., 2004); VAF analysis and MRD monitoring (Schuurhuis et al., 2018).
How PapersFlow Helps You Research Clonal Hematopoiesis in AML Precursor States
Discover & Search
Research Agent uses searchPapers and citationGraph on 'clonal hematopoiesis AML precursor' to map 250M+ OpenAlex papers, revealing Steensma et al. (2015) as central node linking CHIP to WHO classifications (Arber et al., 2016). exaSearch uncovers niche studies on TET2 mutations; findSimilarPapers expands from Jaiswal et al. (2017) to progression risk literature.
Analyze & Verify
Analysis Agent applies readPaperContent to parse Steensma et al. (2015) for CHIP-MDS distinctions, then verifyResponse with CoVe checks mutation frequencies against Delhommeau et al. (2009). runPythonAnalysis computes variant allele frequency statistics from supplementary data using pandas; GRADE grading scores evidence strength for ELN risk models (Döhner et al., 2017).
Synthesize & Write
Synthesis Agent detects gaps in CH progression prediction via contradiction flagging across Jaiswal (2017) and WHO papers, generating exportMermaid diagrams of mutation pathways. Writing Agent uses latexEditText and latexSyncCitations to draft prognostic score tables citing Arber (2016), with latexCompile for publication-ready output.
Use Cases
"Run survival analysis on CHIP mutation VAF data from AML precursor cohorts"
Research Agent → searchPapers 'CHIP VAF AML progression' → Analysis Agent → runPythonAnalysis (pandas Kaplan-Meier plot from Steensma 2015 supplements) → matplotlib survival curve output.
"Draft LaTeX review on WHO CH classifications in myeloid neoplasms"
Synthesis Agent → gap detection (Arber 2016 vs Khoury 2022) → Writing Agent → latexEditText (add CHIP section) → latexSyncCitations (Döhner 2017) → latexCompile (PDF with tables).
"Find code for TET2 mutation simulation in hematopoiesis models"
Research Agent → paperExtractUrls (Delhommeau 2009) → paperFindGithubRepo → githubRepoInspect → Code Discovery workflow outputs Python scripts for epigenetic modeling.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ CH-AML papers via citationGraph from Steensma (2015), producing structured report with GRADE-scored progression risks. DeepScan applies 7-step analysis with CoVe checkpoints to verify TET2 mutation impacts (Delhommeau 2009) against ELN guidelines. Theorizer generates hypotheses on DNMT3A-driven AML trajectories from Jaiswal (2017) and Bullinger (2004) gene-expression data.
Frequently Asked Questions
What defines clonal hematopoiesis in AML precursor states?
CH features somatic mutations like DNMT3A/TET2/ASXL1 in hematopoietic stem cells without cytopenias, distinguishing it from MDS (Steensma et al., 2015).
What methods detect CH mutations?
Next-generation sequencing identifies mutations; WHO guidelines specify thresholds for CHIP diagnosis (Arber et al., 2016; Khoury et al., 2022).
What are key papers on CH and AML?
Steensma et al. (2015, 1859 citations) defines CHIP; Jaiswal et al. (2017, 2448 citations) links CH to myeloid progression; Delhommeau et al. (2009) details TET2 mutations.
What open problems exist in CH research?
Predicting progression from CHIP to AML requires better risk models integrating VAF and co-mutations (Döhner et al., 2017); surveillance protocols for at-risk populations need validation.
Research Acute Myeloid Leukemia Research with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Clonal Hematopoiesis in AML Precursor States with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
Part of the Acute Myeloid Leukemia Research Research Guide